



## **ASX Announcement**

31 May 2021

ASX Market Announcements  
ASX Limited  
Level 4, North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

## **APPENDIX 3Y**

**Melbourne, Australia, 31 May 2021** - Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or the "Company"), a company that develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM®, submits the Appendix 3Y of the following Directors:

- a) Dr Gregory Collier
- b) Dr Ross Murdoch
- c) Mr Matthew McNamara

### **For enquiries, please contact**

Ms Melanie Leydin  
Avecho Biotechnology Limited  
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

### **About Avecho**

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock.

See more here - [avecho.com.au](https://avecho.com.au)

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Avecho Biotechnology Limited
<b>ABN</b>	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Gregory Collier
<b>Date of last notice</b>	31 October 2017

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	31 May 2021
<b>No. of securities held prior to change</b>	<b>Indirect</b> <i>Beacon Super Fund Pty Ltd</i> 1. 2,000,000 fully paid ordinary shares (AVE) 2. 2,250,000 unlisted options (AVEAS)  <i>Gregory Collier is a Director of Beacon Super Fund Pty Ltd</i>
<b>Class</b>	Unlisted options exercisable at \$0.0169 each and expiring 42 months from 31 May 2021, i.e., on 29 November 2024 (AVEAV)
<b>Number acquired</b>	5,990,465
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<b>Indirect</b> <i>Beacon Super Fund Pty Ltd</i> 1. 2,000,000 fully paid ordinary shares (AVE) 2. 2,250,000 unlisted options (AVEAS)  <b>Direct</b> 1. 5,990,465 unlisted options exercisable at \$0.0169 each and expiring 42 months from 31 May 2021, i.e., on 29 November 2024 (AVEAV)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted options granted under the Company's Equity Incentive Plan approved at Annual General Meeting on 31 May 2021.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Avecho Biotechnology Limited
<b>ABN</b>	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ross Murdoch
<b>Date of last notice</b>	2 March 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
<b>Date of change</b>	31 May 2021
<b>No. of securities held prior to change</b>	<b>Direct</b> 1,666,667 fully paid ordinary shares (AVE)
<b>Class</b>	Unlisted options exercisable at \$0.0169 each and expiring 42 months from 31 May 2021, i.e., on 29 November 2024 (AVEAV)
<b>Number acquired</b>	3,993,644
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<b>Direct</b> <ol style="list-style-type: none"> <li>1,666,667 fully paid ordinary shares (AVE)</li> <li>3,993,644 unlisted options exercisable at \$0.0169 each and expiring 42 months from 31 May 2021, i.e., on 29 November 2024 (AVEAV)</li> </ol>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted options granted under the Company's Equity Incentive Plan approved at Annual General Meeting on 31 May 2021.

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

+ See chapter 19 for defined terms.

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Avecho Biotechnology Limited
<b>ABN</b>	32 056 482 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Matthew Patrick McNamara
<b>Date of last notice</b>	13 January 2020

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Mlaks Pty Ltd ITF M and L McNamara Super Fund  <i>Matthew McNamara is a beneficiary of the fund</i>
<b>Date of change</b>	31 May 2021
<b>No. of securities held prior to change</b>	Nil
<b>Class</b>	Unlisted options exercisable at \$0.0169 each and expiring 42 months from 31 May 2021, i.e., on 29 November 2024 (AVEAV)
<b>Number acquired</b>	3,993,644
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Nil
<b>No. of securities held after change</b>	<b>Indirect</b> <i>Mlaks Pty Ltd ITF M and L McNamara Super Fund</i> 3,993,644 Unlisted options exercisable at \$0.0169 each and expiring 42 months from 31 May 2021, i.e., on 29 November 2024 (AVEAV)

+ See chapter 19 for defined terms.



## Appendix 3Y

### Change of Director's Interest Notice

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Unlisted options granted under the Company's Equity Incentive Plan approved at Annual General Meeting on 31 May 2021.
---	---

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.